Axsome Therapeutics, Inc. (0HKF.L)
USD 94.11
(0.14%)
USD 94.11
(0.14%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 186.37 Million USD | 96.84% |
| 2022 | 94.68 Million USD | 90.47% |
| 2021 | 49.71 Million USD | -0.83% |
| 2020 | 50.12 Million USD | 151.44% |
| 2019 | 19.93 Million USD | 188.46% |
| 2018 | 6.91 Million USD | -30.42% |
| 2017 | 9.93 Million USD | 1.98% |
| 2016 | 9.73 Million USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 4.48 Million USD | 17.18% |
| 2013 | 3.82 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 191.8 Million USD | 1.25% |
| 2024 Q1 | 189.42 Million USD | 1.64% |
| 2023 Q2 | 184.71 Million USD | 25.04% |
| 2023 Q1 | 147.72 Million USD | 56.02% |
| 2023 FY | 186.37 Million USD | 96.84% |
| 2023 Q4 | 186.37 Million USD | 0.43% |
| 2023 Q3 | 185.57 Million USD | 0.47% |
| 2022 Q2 | 94.16 Million USD | 87.29% |
| 2022 Q4 | 94.68 Million USD | 0.37% |
| 2022 Q1 | 50.27 Million USD | 1.15% |
| 2022 FY | 94.68 Million USD | 90.47% |
| 2022 Q3 | 94.33 Million USD | 0.17% |
| 2021 Q2 | 50.05 Million USD | -0.14% |
| 2021 Q4 | 49.71 Million USD | -0.69% |
| 2021 FY | 49.71 Million USD | -0.83% |
| 2021 Q3 | 50.05 Million USD | 0.0% |
| 2021 Q1 | 50.12 Million USD | 0.0% |
| 2020 FY | 50.12 Million USD | 151.44% |
| 2020 Q1 | 20.11 Million USD | 0.89% |
| 2020 Q2 | 20.29 Million USD | 0.89% |
| 2020 Q3 | 48.02 Million USD | 136.68% |
| 2020 Q4 | 50.12 Million USD | 4.37% |
| 2019 Q3 | 19.75 Million USD | 0.9% |
| 2019 Q1 | 19.35 Million USD | 180.04% |
| 2019 FY | 19.93 Million USD | 188.46% |
| 2019 Q2 | 19.57 Million USD | 1.17% |
| 2019 Q4 | 19.93 Million USD | 0.9% |
| 2018 Q3 | 7.72 Million USD | -8.79% |
| 2018 Q1 | 9.2 Million USD | -7.3% |
| 2018 FY | 6.91 Million USD | -30.42% |
| 2018 Q4 | 6.91 Million USD | -10.55% |
| 2018 Q2 | 8.47 Million USD | -8.0% |
| 2017 Q1 | 9.85 Million USD | 1.19% |
| 2017 FY | 9.93 Million USD | 1.98% |
| 2017 Q4 | 9.93 Million USD | -1.59% |
| 2017 Q3 | 10.09 Million USD | 1.2% |
| 2017 Q2 | 9.97 Million USD | 1.19% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | 9.73 Million USD | 0.0% |
| 2016 Q4 | 9.73 Million USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2015 FY | - USD | -100.0% |
| 2015 Q2 | 10.9 Million USD | 0.0% |
| 2015 Q4 | - USD | -100.0% |
| 2015 Q3 | 15.13 Million USD | 38.77% |
| 2015 Q1 | - USD | -100.0% |
| 2014 FY | 4.48 Million USD | 17.18% |
| 2014 Q4 | 4.48 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 FY | 3.82 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -410.105% |
| Dynavax Technologies Corporation | 256.91 Million USD | 27.457% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -348.797% |
| Perrigo Company plc | 4.07 Billion USD | 95.425% |
| Illumina, Inc. | 2.26 Billion USD | 91.761% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.466% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -18537.2% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 98.049% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 98.69% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -7.263% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 93.105% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -590.522% |
| Waters Corporation | 2.35 Billion USD | 92.088% |
| Biogen Inc. | 7.33 Billion USD | 97.46% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -389.114% |
| Evolus, Inc. | 126.54 Million USD | -47.276% |
| Adicet Bio, Inc. | 17.7 Million USD | -952.771% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -331.746% |
| bluebird bio, Inc. | 330.32 Million USD | 43.579% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 65.547% |
| FibroGen, Inc. | 170.45 Million USD | -9.338% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 93.186% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -792.405% |
| Homology Medicines, Inc. | 44.05 Million USD | -323.054% |
| Geron Corporation | 85.89 Million USD | -116.966% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 92.228% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 58.124% |
| Myriad Genetics, Inc. | 145 Million USD | -28.532% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -14691.429% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -61.576% |
| Zoetis Inc. | 6.8 Billion USD | 97.26% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -4133.803% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 91.403% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 83.563% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 76.946% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -413.096% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 87.178% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -222.042% |
| Verastem, Inc. | 41.55 Million USD | -348.473% |
| Nektar Therapeutics | 230.4 Million USD | 19.11% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -5962.85% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 86.657% |
| OPKO Health, Inc. | 326.56 Million USD | 42.929% |
| Exelixis, Inc. | 189.94 Million USD | 1.881% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 56.496% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -123325.166% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | -34.653% |
| Imunon, Inc. | 1.13 Million USD | -16258.566% |
| Blueprint Medicines Corporation | 774.12 Million USD | 75.925% |
| Insmed Incorporated | 1.2 Billion USD | 84.521% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 87.569% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -227.037% |
| TG Therapeutics, Inc. | 110.79 Million USD | -68.213% |
| Incyte Corporation | 38.28 Million USD | -386.776% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 78.761% |